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During the last decade, the administration of
heparin followed by oral anticoagulation therapy for a
period of 3 to 6 months has been established as the
standard treatment of lower extremity deep vein
thrombosis (DVT). Traditionally, the main objectives
of DVT treatment have been the prevention of death
from pulmonary embolism, the reduction of morbidi-
ty from an acute event, and the minimizing of recur-
rences. In recent years, interest in the prevention of
long-term post-thrombotic sequelae has increased
because of the expanding awareness of their impact on
patient quality of life and their considerable drain of
health care resources.
The factors that influence the long-term clinical
outcomes of DVT are not completely understood. A
number of studies have shown that between 30% and
80% of patients with acute DVT will have symptoms
of post-thrombotic syndrome (PTS) develop between
3 and 13 years after the initial diagnosis.1-6 The devel-
opment of chronic venous insufficiency (CVI) associ-
ated with PTS has been related to residual vein
obstruction and the presence of reflux caused by
valvular incompetence. In fact, approximately 30% to
50% of DVT are not completely resolved 6 to 12
months after diagnosis.7-10 Currently, it is not possi-
ble to predict which patients will undergo complete
resolution after an acute DVT or which patients will
have PTS develop.
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Objective: The purpose of this study was to assess the rate of deep vein thrombosis
(DVT) resolution and DVT outcomes as functions of the level of oral anticoagulation
therapy achieved with warfarin.
Methods: In 33 consecutive patients, a series of 35 limbs with acute symptomatic DVT was
followed throughout 1 year of anticoagulation therapy. All the patients underwent 5 days
of intravenous unfractionated sodium heparin therapy that was adjusted in dose to prolong
the activated thromboplastin time to 2.0 to 2.5 times the control. In addition, warfarin was
administered for a period of 6 months, with a target international normalized ratio (INR)
between 2.0 and 3.0. All the patients underwent venous duplex scanning and physical exam-
ination at the time of diagnosis and at 1 week, 1 month, 3 months, 6 months, and 1 year.
Results: At the end of the 1-year study period, the rate of complete DVT resolution was
68%. The median INR values in patients with complete DVT resolution were signifi-
cantly higher than those of patients with incomplete DVT resolution after 1, 3, and 6
months of treatment with warfarin. In addition, the proportion of patients with INR
values below therapeutic range was significantly higher in patients with incomplete DVT
resolution than in patients with complete DVT resolution after 1, 3, and 6 months of
treatment with warfarin. The presence of occlusive thrombi was associated with incom-
plete DVT resolution. Of the patients with occlusive thrombi, 62% had chronic venous
insufficiency symptoms develop, whereas only 11% of the patients with nonocclusive
thrombi (P = .003) had these symptoms develop.
Conclusion: Despite 6 months of oral anticoagulant therapy, almost one third of throm-
bi did not resolve completely. The INR values were significantly higher in those patients
with complete DVT resolution. These results suggest that the maintenance of an INR
level between 2.0 and 3.0 throughout oral anticoagulation therapy will minimize the
rate of incomplete DVT resolution. (J Vasc Surg 1999;30:805-12.)
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the lower limit of the activated partial thromboplas-
tin time (aPTT) during heparin therapy and recur-
rent DVT has been recently documented by Hull et
al.11 However, there have been no recent studies that
investigated a possible correlation between the inter-
national normalized ratio (INR) levels achieved with
warfarin therapy and either DVT resolution or the
development of PTS symptoms.
In this study, we prospectively assessed with ser-
ial venous duplex scanning (VDS) the degree and
rate of DVT resolution during a 1-year period and
correlated INR values at different time intervals with
DVT outcomes.
METHODS
A series of 57 consecutive patients (22 women,
35 men) in whom acute DVT of the legs was diag-
nosed with duplex ultrasound scanning in our vascu-
lar laboratory were asked to participate in the study.
The mean age was 65.2 ± 10.3 years (range, 45 to 87
years). The patients were referred by the physicians
who were responsible for their DVT treatment. The
protocol and consent forms both were approved by
the hospital Institutional Review Board.
All the patients underwent 5 days of standard
intravenous unfractionated heparin treatment adjust-
ed in dose to prolong the aPTT between 2.0 and 2.5.
After the fifth day of heparin therapy, oral sodium
warfarin was initiated and continued for at least 6
months, adjusted in dose to achieve an INR level
between 2.0 and 3.0. At presentation and during
subsequent visits for each patient, an experienced vas-
cular technologist filled out a questionnaire that
included signs and symptoms of both DVT and PTS.
VDS was performed at patient presentation and
at 1 week, 1 month, 3 months, 6 months, and 1 year
thereafter. A color-coded high definition scanner
(Ultramark 9 HDI, Advanced Technology Labora-
tories, Bothell, Wash) with a 5-MHz pulsed Doppler
scan was used for all VDS. The patients were placed
supine in a 10-degree to 20-degree reverse Trende-
lenburg position for the examination of common
and superficial femoral veins. The popliteal, posteri-
or tibial, anterior tibial, gastrocnemius, and peroneal
veins were examined with the leg in a dependent
position. Thrombi that extended to the popliteal,
superficial femoral, common femoral, or iliac veins
were reported to be proximal, and thrombi that
were restricted to the calf veins (posterior tibial, gas-
trocnemius, soleil, peroneal, and anterior tibial)
were considered to be distal. All the veins were
imaged in longitudinal and transverse planes. The
criteria that were indicative of DVT included
absence of both spontaneous and augmented flow,
presence of intraluminal echogenic material, partial
or total inability to compress vein with gentle probe
pressure, and dilation of the thrombosed vein. The
approximate percentage of the venous lumen
occluded by the thrombus was calculated and the
outcomes were divided into the following four cate-
gories: worsening, no change, improvement, or
complete resolution. Worsening indicated extension
of the clot to other previously unaffected venous
segments. No change was reported if the thrombus
remained confined to the same venous segment
without reduction in its size and with no recanaliza-
tion. Improvement indicated signs of recanalization
without complete compressibility of the venous seg-
ment with the duplex scan probe or reduction in the
clot size as compared with a previous scan. A clot
was considered to be completely resolved when the
venous segment was fully compressible by the probe
and there was complete disappearance of any echo-
genic intraluminal filling defect.
Statistical analysis consisted of the calculation of
the average and standard deviation for normally dis-
tributed variables and the calculation of the median
and 25% to 75% interquartile ranges for variables
that did not pass a normality test. Accordingly, the
INR results, which were not normally distributed,
were compared with a nonparametric test (Mann-
Whitney rank sum test). The proportions were com-
pared with the c 2 test or the Fisher exact test when
appropriate. All the tests were two-sided, and a
probability of .05 was considered to be significant.
RESULTS
Of the 57 patients who initially were recruited to
participate in the study, three declined to participate,
13 dropped out during the study, five had incom-
plete INR data, and three died of causes other than
pulmonary embolism before the completion of the
1-year follow-up period. Therefore, a total of 33
patients (17 men, 16 women) completed the study.
The patients who were excluded from the analysis
because of incomplete INR follow-up information
were similar to the patients who were included in the
study with regard to: average age at presentation (65
6 10 years and 56 6 18 years, respectively; P = .07),
rates of proximal DVT (86% and 89%, respectively;
P = 1) and occlusive DVT (48% and 37%, respec-
tively; P = .56), and the rate of complete DVT reso-
lution (44% and 68%, respectively; P = .21). Two
patients had bilateral DVT, so there were 35 legs
with DVT suitable for analysis. The average age of
the patients was 65.9 ± 12.3 years (range, 45 to 
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82 years). No bleeding complications were encoun-
tered during the study period. During the first 24
hours of heparin therapy, 52% of the patients had
aPTT values within the target range (2.0 to 2.5
times control). Seven patients underwent extended
oral anticoagulation therapy for 1 year (three in the
nonresolution group and four in the resolution
group; P = .67). Otherwise, all the patients under-
went 6 months of warfarin therapy.
At presentation, 18 thrombi (51%) completely
occluded venous lumens. Regarding distribution
within the leg, 11 clots (31.4%) were proximal with-
out calf extension, 19 (54.2%) extended above and
below the popliteal vein, and five (14.3%) were lim-
ited to the calf.
The proportion of patients with complete DVT
resolution on VDS was 6% (2 of 33) at 1 week, 15%
(5 of 33) at 1 month, 39% (13 of 33) at 3 months,
70% (23 of 33) at 6 months, and 70% at 1 year.
There were no symptomatic DVT recurrences in
veins that had clot resolution during the follow-up
period. However, two patients were found to have
progression on their 1-week and 3-month scans,
with incomplete DVT resolution at 1 year. Of the
limbs with nonocclusive DVT, 83% had complete
resolution as opposed to only 38% among those with
occlusive thrombi (P = .01). On the other hand,
there were no statistically significant differences
regarding DVT outcomes of proximal and distal
thrombi at 1 year (P = .14). Eight patients had a his-
tory of previous DVT: four in the complete resolu-
tion group (17.4%) and four in the partial resolution
group (33.3%; P = .4). Accordingly, 50% (4 of 8) of
the limbs with previous DVT resolved as compared
with 70.3% (19 of 27) in those patients without a
history of DVT (P = .4). Of the two patients with
bilateral thrombi, one had incomplete resolution in
both limbs at 1 year and the other had complete
DVT resolution in one limb and partial resolution in
the contralateral limb. The limb with complete reso-
lution had a totally occlusive thrombus on presenta-
tion that affected the posterior tibial and popliteal
veins. The limb with partial resolution had a totally
occlusive thrombus that extended from the calf to
the common femoral vein.
Table I compares the presence of a number of
factors at the time of DVT diagnosis as a function of
final outcome. The only factor that was significantly
more prevalent in legs with incomplete DVT resolu-
tion was the presence of occlusive thrombus on pre-
sentation.
Table II details the median and 25% to 75%
interquartile range INR values initially and during
the follow-up period according to complete throm-
bus resolution. The patients with complete DVT
resolution had significantly higher INR values than
did the patients with partial resolution after 1, 3, and
6 months of treatment. No significant differences in
INR values were observed during the first week of
warfarin treatment.
The proportion of patients with subtherapeutic
INR values (<2.0) was significantly higher in the
group of patients with incomplete DVT resolution
at 1, 3, and 6 months after the initiation of treat-
ment (Table III). The INR values were not signifi-
cantly different throughout the study follow-up
period regarding proximal thrombi or complete ves-
sel occlusion at the time of DVT diagnosis (Tables
IV and V).
One year after DVT diagnosis, deep vein reflux
was detected in 25% of the limbs and PTS symptoms
were reported by patients in 31% of the affected
limbs. In patients with occlusive thrombi, 62.5% had
symptoms of CVI develop that were suggestive of
PTS versus 11% among those patients with nonocclu-
sive thrombi (P = .003). The prevalence of CVI symp-
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Table I. Demographic and clinical factors at the time of deep vein thrombosis diagnosis in relation to
deep vein thrombosis outcome
Resolution (n = 22) Nonresolution (n = 11) P value
Age (years) 65 ± 12 67 ± 8 .13*
Male sex 10 (45%) 6 (54%) .72†
Cancer 5 (22%) 2 (18%) 1.00†
Totally occlusive DVT 7 (32%) 9 (83%) .01†
Proximal DVT 17 (77%) 11(100%) .14†
Distal DVT 5 (23%) 0 (0%) .14†
Target aPTT within 24 hours 13 (59%) 4 (36%) .29†
DVT, Deep vein thrombosis; aPTT, activated partial thromboplastin time.
*Independent t test.
†With c 2 test or Fisher exact test.
toms was not significantly different between patients
with proximal (34%) or distal (40%) DVT (P = 1.0).
The most prevalent symptoms of PTS were leg edema
(28.6%) and tenderness (20%). None of the patients
had venous ulceration develop during the study peri-
od. The INR results were not significantly different
during the follow-up period between patients who
did and did not have CVI symptoms develop (Table
VI). The only exception occurred in the comparison
of patients with nontherapuetic INR levels and occlu-
sive thrombi with patients who had at least two ther-
apeutic INR levels and nonocclusive thrombi in which
CVI symptoms developed in 67% (4 of 6) and 6% (1
of 16) of the patients, respectively (P = .009).
DISCUSSION
Most deep veins recanalize by a process of clot
lysis and retraction during the first year after an
episode of acute DVT. However, a significant num-
ber of thrombi remain unchanged or undergo only
partial resolution. Symptomatic chronic venous dis-
ease characteristic of PTS results from persistence of
obstruction to flow and from reflux caused by
venous valvular incompetence.
Duplex ultrasound scanning is a useful tool for
the assessment of DVT outcome. Recanalization,
retraction, development of collaterals, and presence
of valvular incompetence and reflux are clearly shown
with this noninvasive technique. In addition to pro-
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Table II. Results of serial prothrombin time tests expressed as international normalized ratio values (medi-
an and 25% to 75% interquartile ranges) in relation to deep vein thrombosis outcome
INR results
Outcome Initial 1 week 1 month* 3 months* 6 months†
Resolved DVT 1.1 (1.0 to 1.2) 2.2 (1.6 to 2.5) 2.3 (2.0 to 2.8) 2.0 (1.7 to 2.5) 2.2 (1.8 to 2.5)
Not resolved DVT 1.1 (1.0 to 1.2) 1.8 (1.2 to 2.9) 1.5 (1.2 to 1.8) 1.6 (1.2 to 1.8) 1.6 (1.5 to 1.9)
INR, International normalized ratio; DVT, deep vein thrombosis.
*P < .01 with Mann-Whitney test.
†P < .05.
Table IV. Results of serial prothrombin time tests expressed as international normalized ratio values
(median and 25% to 75% interquartile ranges) in relation to proximal or distal deep vein thrombosis on
presentation
INR results
Outcome Initial 1 week 1 month* 3 months 6 months
Proximal DVT 1.2 (1.2 to 1.2) 2.1 (1.3 to 2.4) 2.0 (1.6 to 2.3) 1.8 (1.5 to 2.2) 1.9 (1.6 to 2.5)
Distal DVT 0.9 (0.9 to 0.9) 2.2 (1.8 to 2.5) 2.8 (2.2 to 2.9) 2.1 (1.2 to 2.2) 2.5 (1.8 to 2.6)
INR, International normalized ratio; DVT, deep vein thrombosis.
*P < .05 with Fisher exact test.
Table III. Proportion of patients with international normalized ratio results less than 2.0, between 2.0
and 3.0, and more than 3.0 in relation to deep vein thrombosis outcome
INR < 2.0 INR 2.0 to 3.0 INR > 3.0
Resolved Nonresolved Resolved Nonresolved Resolved Nonresolved
Initial 100% (22/22) 91% (10/11) 4% (1/22) 0% (0/11) 0% (0/22) 0% (0/11)
1 week 41% (9/22) 54% (6/11) 60% (13/22) 54% (6/11) 4.5% (1/22) 0% (0/11)
1 month 23%* (5/22) 82%* (9/11) 60% (13/22) 27% (3/11) 18% (4/22) 0% (0/11)
3 months 50%* (11/22) 91%* (10/11) 50% (11/22) 18% (2/11) 4.5% (1/22) 0% (0/11)
6 months 32%* (7/22) 82%* (9/11) 64%* (14/22) 9%* (1/11) 4.5% (1/22) 18% (2/11)
INR, International normalized ratio
*P < .05 with Fisher exact test.
viding essential information on venous function,
duplex ultrasound scanning can reveal the exact loca-
tion of thrombi and valvular insufficiency, making it
a valuable tool for the diagnosis of PTS.12-16
Recently, a number of studies have assessed the
outcome of lower extremity DVT with serial duplex
testing.8-10,15,17-21 Although these studies reported
different rates of clot resolution and development of
reflux, most of them showed that recanalization is
not as slow as was previously suggested and that
reflux occurs in more than half of the legs with DVT.
This study revealed that only 68% of thrombi under-
go complete resolution within 1 year of DVT diag-
nosis. The most significant changes regarding DVT
outcome occurred by the third month examination,
and few changes occurred between the sixth and the
12th month examination. Similar results were
reported by Murphy and Cronan,8 who found that
thrombus resolution, if recanalization of vein throm-
bi were to occur, should be evident within 6 months
of the diagnosis of DVT. A different study found
complete recanalization of almost all thrombosed
vein segments at 1 year.15
Our results indicate that thrombi that completely
occlude the venous lumen are associated with incom-
plete DVT resolution. Different results were provid-
ed by van Ramshorst et al,9 who did not find differ-
ences in DVT regression in partially or totally
occluded vessels. Regarding location of thrombi, we
did not find a higher proportion of proximal DVT in
patients with incomplete clot resolution as did Lea-
Thomas and McCallister22 or a faster recanalization
rate among cases with distal DVT as did Franzeck et
al.6 Therefore, our results agree with the results of
other investigators who have found no difference 
in resolution rates between different venous seg-
ments.8,23
In this study, early adequate anticoagulation
therapy did not correlate with complete DVT reso-
lution at 1 year because the INR levels in the first
week of treatment were similar in patients with com-
plete or incomplete thrombus resolution (Table II).
Similarly, other investigators have reported no dif-
ference in early propagation of thrombi24 or even
thrombi extension25 despite early therapeutic levels
of anticoagulation therapy. Perhaps the recommend-
ed aPTT range (2 to 2.5 times control) is not as ade-
quate as suggested because it seems to have little
influence on the improvement of long-term out-
comes in patients with DVT. On the other hand, a
recent analysis of three trials has documented a sig-
nificant association between early achievement of
therapeutic aPTT and recurrent DVT.11 In our
study, however, we were more interested in the cor-
relation of long-term oral anticoagulation therapy
and DVT outcomes. Indeed, after the first month of
treatment and at the 3-month and 6-month follow-
up periods, the patients with complete resolution
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Table V. Serial prothrombin time tests expressed as international normalized ratio (median and 25% to
75% interquartile ranges) in relation to vessel occlusion at the time of deep vein thrombosis diagnosis
INR results
Outcome Initial 1 week 1 month* 3 months 6 months
Occlusive DVT 0.9 (0.9 to 0.9) 2.1 (1.4 to 2.4) 1.8 (1.4 to 2.2) 1.9 (1.4 to 2.1) 2.0 (1.6 to 2.5)
Nonocclusive DVT 1.2 (1.2 to 1.2) 2.2 (1.3 to 2.5) 2.3 (1.9 to 2.6) 1.7 (1.5 to 2.4) 2.0 (1.6 to 2.6)
INR, International normalized ratio; DVT, deep vein thrombosis.
*P < .05 with Mann-Whitney test.
Table VI. Serial prothrombin time tests expressed as international normalized ratio (median and 25% to
75% interquartile ranges) in relation to symptoms of chronic venous insufficiency 1 year after deep vein
thrombosis diagnosis
INR results
Outcome Initial 1 week 1 month* 3 months 6 months
No CVI symptoms 1.2 (1.2 to 1.2) 2.2 (1.3 to 2.4) 1.8 (1.5 to 2.4) 1.8 (1.5 to 2.3) 2.2 (1.7 to 2.5)
CVI symptoms 0.9 (0.9 to 0.9) 2.0 (1.4 to 2.5) 1.8 (1.4 to 2.1) 2.0 (1.5 to 2.2) 1.8 (1.4 to 2.4)
INR, International normalized ratio; CVI, chronic venous insufficiency.
P <.05 with Mann-Whitney test.
had significantly higher INR values than did the
patients without complete DVT resolution.
Recent studies have correlated DVT outcome
with the degree of plasma fibrinolytic activity.
Arcelus et al10 reported higher levels of plasminogen
activator inhibitor in patients with incomplete reso-
lution. Similarly, Killewich et al26 have reported sig-
nificant enhancement of endogenous fibrinolysis,
mediated by increased tissue plasminogen activator
during thrombus regression.
Our results show that 62% of patients with occlu-
sive thrombi had CVI symptoms develop as opposed
to 11% in patients with nonocclusive thrombi (P =
.003). Almost two thirds of the patients with a com-
bination of subtherapeutic INR levels and occlusive
DVT had CVI symptoms develop. On the contrary,
only 6% of patients with INR levels within the desired
range had CVI symptoms develop. Similar to other
studies, we did not find an association between the
location of the DVT on presentation and the subse-
quent development of CVI symptoms.3,20 These
results indicate that the degree of occlusion caused by
the thrombi may have more influence on the long-
term DVT outcomes than the location of the throm-
bi. This issue remains controversial because some
authors have found a more benign outcome in DVT
located distal to the knee,6,15,27 whereas others have
reported a correlation between patent and competent
veins in the calf and favorable outcome.1
In conclusion, in this preliminary study, we have
reported that two thirds of DVT resolve within 1
year of diagnosis and almost one third of the cases
have symptoms develop that are suggestive of PTS.
A number of factors, including vessel occlusion
caused by thrombi and the level of oral anticoagula-
tion therapy, have been found to be associated with
DVT outcome 1 year after diagnosis. We agree with
van Ramshorst et al9 that serial duplex scanning has
enormous potential for the assessment of DVT out-
come, which may allow for the improved identifica-
tion of patients with poor prognoses, a better defin-
ition of their clinical management, and a reduction
in their risk of the development of CVI. Further
studies with a larger number of patients and a longer
period of follow-up examination are necessary to
establish a stronger correlation between the level of
oral anticoagulation therapy achieved 3 to 6 months
after acute DVT and long-term outcomes, such as
DVT resolution and the development of PTS.
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Dr D. Eugene Strandness, Jr (Seattle, Wash). I had
the opportunity of reviewing this manuscript, and there
are some interesting facts that have emerged from this
study. We all recognize that different investigators in the
past few years have shown us that there are issues that we
should be dealing with in the long-term follow-up and
treatment of patients with deep venous thrombosis. We
know there is some element of lysis, fragmentation, and
retraction of the thrombus that regularly occurs after an
episode of deep vein thrombosis. The extent to which this
occurs is variable and is influenced by factors that are not
completely understood. What are some of these factors?
The patient’s own lytic system is obviously important. The
extent of the thrombosis is obviously important. And, of
course, the key point in this study is the level of anticoag-
ulation attained with both heparin and warfarin therapy.
Our studies have shown that thrombus stability is
clearly affected by the level of anticoagulation, particular-
ly when heparin is used in the early phase of the therapy.
In fact, we have a paper coming out in the Journal of
Vascular Medicine that will show that a good share of the
time with unfractionated heparin thrombus extension
occurs even though you may think that your patient is
adequately anticoagulated.
Warfarin therapy has shown, at least in our studies, that
progression and extension of existing thrombi is not
uncommon. However, we did not prospectively look at the
international normalized ratio (INR) levels as was done in
this study. It appears that this is a factor and further sub-
stantiates how important this management is in our patient
follow-up. This study has shown that level of thrombus
lysis is not only dependent on the level of the INR but also
on the thrombus load. This would appear to make good
sense, and I cannot see any major flaws in this study. The
proportion of those patients with an INR between 2 and 3
was significant at only 1 month. However, even given these
results, they were not predictive of clinical outcome, which
is a bit disappointing. In other words, what is the relevance
of the finding that was reported in this study?
As we suspect, the use of low–molecular weight heparin
therapy may encourage thrombus stability during the acute
phase of therapy. However, we have a drug now that
appears to provide us with a stable thrombus in the first 5
days, but we have warfarin, which may not do as well in the
long term. I frankly believe that warfarin therapy is equally
as difficult as unfractionated heparin therapy, and I think
that this study clearly has shown this.
I wonder if Dr Caprini would answer the following
questions and perhaps speculate a bit on the future. Do
you think that the failure to correlate outcome with INR
is a matter of numbers? Do you think that a larger study is
in order to examine this problem in some depth? I think
this is probably realistic given the fact that we now realize
that extension and rethrombosis may be a more common
problem than we anticipated. Is it possible with the new
interest in low–molecular weight heparin therapy that we
will soon be looking at a new oral anticoagulant, an oral
agent that may accomplish what we fail to do with war-
farin? And then finally, what is the role perhaps of long-
term therapy with low–molecular weight heparin if one
were to discount the cost involved? I think Dr Hull sug-
gested that there is a study going on in this country with
low–molecular weight heparin therapy up to 10 months. I
wonder, Dr Caprini, if you have any ideas how this might
be implemented.
I want to thank the Society for the privilege of address-
ing this paper. It was well done. Thank you very much.
Dr Joseph A. Caprini. Thank you very much, Dr
Strandness. It was an honor to have you comment on this
paper, and I am happy I am still standing.
First of all, for your findings as far as thrombus exten-
sion, we have seen that as well. I think that it indicates
there are some shortcomings with monitoring unfraction-
ated heparin that result in thrombus extension.
As far as clinical outcomes, the study is too small. I real-
ly think that this should be just a stimulus to all of us, and I
also agree that warfarin has shortcomings. I think we all
need to get some of the finest vascular laboratories, of which
you are an excellent example, to pool their results in a
prospective analysis of this problem with significant num-
bers. Is this really true? Is it not really true? It looks like it is
worth trying to do in any event. 
DISCUSSION
Low–molecular weight heparin, a very interesting com-
pound, as you know, not only has a specificity for factor
X19/antithrombin-3 complex, but it has been shown to
decrease the von Willebrand factor. Heparins stimulate the
fibrinolytic system. They have an affect on IIB/IIIa, a step
in platelet aggregation that provides anticoagulant therapy.
And, if you take a look at the trials, total hips, total knees,
where warfarin or oral anticoagulants have been pitted
against low–molecular weight heparin, in every single case,
low–molecular weight heparin has come out statistically sig-
nificantly better. 
The only question is whether those clots that they are
preventing are really important long term. So, my point is
that I agree with you 100%. I think that now that we have
low–molecular weight heparin, we have to establish what is
going on with the standard warfarin therapy, but we need a
prospective randomized trial in which we use it initially and
convert to warfarin and we also use it completely for the
entire treatment period. It is my bias on the basis of some
of those hematologic things that I have said. There are a
number of heparins that have shown promise in the cancer
patient, and I think this is worth a full and complete trial.
Dr John J. Ricotta (Stony Brook, NY). Dr Caprini, I
enjoyed your presentation. You associated two factors with
good long-term results. One was incomplete occlusion of
the vein wall, and the other was the INR. Was the INR
association independent of the complete versus incom-
plete thrombosis, or were your numbers too small to tell?
Dr Caprini. That is an excellent question. I think, as Dr
Strandness pointed out, that the outcomes are related to the
clot load—there is no question about that—and I think the
outcomes are also related to the level of anticoagulation.
Now we do not have enough numbers to know whether
they are independent, but my bias is that warfarin therapy is
inferior for this. One of the reasons for this may even be
that, as physicians, we all tend to underdose our patients. I
do not say that without a tremendous respect. I know that
for years I have been treating lots of patients and really sort
of poo-pooing the bleeding problem. Then, within 1
month, I had two deaths with perfect INRs, everything fol-
lowed to the letter, so that I think it is a very dangerous sit-
uation here with this drug and it is a very complex interre-
lationship between those two factors. I think it would take
a bigger study to sort it out, but I think that the question
you ask must be answered.
Dr Ricotta. The second question I have is: if you go
ahead with a larger study, would you anticipate doing any
sort of screening for coagulation disorders or fibrinolytic
disorders? If so, what would you plan to look at in these
patients?
Dr Caprini. Another wonderful question that brings
up a whole host of other issues. First of all, if I were
designing the study, I would do their leiden status, pro-
thrombin 2021A, and homocystinemia because they are
three congenital defects and when the one is positive the
other two may be positive. As you know, with the leiden
defect, 20% of people with a history of thrombosis will test
positive, so it is well worth doing. So, I would do that, but
I think I would blind it because we do not know what to
do with leiden-positive patients. So, I would not muddy
the waters with that.
To answer the second part of your question, we had
presented for this society previously that there was a fibri-
nolytic shutdown in certain patients that we could docu-
ment on the 1-day blood draw that we could correlate
with nonresolution at 1 year. In future studies, I would do
a more extensive analysis of the fibrinolytic system, and
blind those data until 1 year to see what those data would
show in terms of the eventual outcome of the thrombus.
Dr David S. Sumner (Springfield, Ill). Instead of tak-
ing resolved clots and telling what the average INR was,
could you turn the data around the other way and tell us
what proportion of clots resolved when the INR was
greater than 2 versus what proportion of clots resolved
when it was less than 2? In other words, look at the data
in the opposite direction.
Dr Caprini. I am going to have to think about that. I
am not sure that I know my numbers perfectly. My bias is
that the INRs are much better when the clots resolve, but
I would have to think about that question.
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